AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Metalla Royalty & Streaming Ltd.
Video analysis: MTA
All videosNo video analysis for this stock yet. Request one from our team.
News: MTA
Are You Looking for a Top Momentum Pick? Why Metalla Royalty & Streaming Ltd.
Does Metalla Royalty & Streaming Ltd. (MTA) have what it takes to be a top stock pick for momentum investors?
Are Basic Materials Stocks Lagging Metalla Royalty & Streaming (MTA) This Year?
Here is how Metalla Royalty & Streaming Ltd. (MTA) and SSAB (SSAAY) have performed compared to their sector so far this year.
METALLA REPORTS RECORD FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2026 AND PROVIDES ASSET UPDATES
( All dollar amounts are in thousands of United States dollars unless otherwise indicated, except for shares, per ounce, and per share amounts) TSXV: MTA NYSE American: MTA VANCOUVER, BC, Aug. 13, 2026 /PRNewswire/ -- Metalla Royalty & Streaming Ltd. ("Metalla" or the "Company") (TSXV: MTA) (NYSE American: MTA) announces its operating and financial results for the three and six months ended June 30, 2026.
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
IDE892 is a potential best-in-class PRMT5 inhibitor with 1,400-fold selective MTA-PRMT5 cooperative binding vs SAM-PRMT5 cooperative binding, and CYP3A4 IC50 greater than 45 micromolar with no time-dependent inhibition of the 7 major cytochrome P450s IDE892 Phase 1/2 escalation has cleared multiple dose cohorts and projected efficacious target exposures have been achieved to initiate the Part 2 monotherapy expansion. The IDE892 escalation is ongoing in parallel and the MTD has not yet been reached IDE892 and IDE397 combination escalation are ongoing in MTAP NSCLC and PDAC, and IDE892 and pan-RAS combination FPI in MTAP PDAC is targeted for H2 2026 MTAP-deletion is estimated to occur in up to 40% of PDAC and ~15% of NSCLC IDEAYA is targeting a MTAP/CDKN2A, KRAS, and Pancreatic Cancer R&D Day in Q4 2026.
METALLA ANNOUNCES VOTING RESULTS FROM ANNUAL GENERAL MEETING AND INVESTMENT FROM SANDEEP SINGH
TSXV: MTA NYSE AMERICAN: MTA VANCOUVER, BC, June 23, 2026 /PRNewswire/ - Metalla Royalty & Streaming Ltd. ("Metalla" or the "Company") (NYSE American: MTA) (TSXV: MTA) is pleased to announce the voting results for its annual general meeting of shareholders held on June 23, 2026 (the "Meeting") where all director nominations and other items recommended by the board of directors of the Company (the "Board") were approved.
METALLA PUBLISHES 2026 ASSET HANDBOOK AND ANNUAL LETTER TO SHAREHOLDERS
TSXV: MTA NYSE AMERICAN: MTA VANCOUVER, BC, June 23, 2026 /PRNewswire/ - Metalla Royalty & Streaming Ltd. ("Metalla" or the "Company") (NYSE American: MTA) (TSXV: MTA) is pleased to announce the release of its 2026 Asset Handbook outlining the Company's high-quality gold, silver, and copper production, development, and exploration assets, as well as Mineral Reserve and Mineral Resource data.
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties IDE892 has a CYP3A4 IC50 greater than 45 micromolar, and did not show time dependent inhibition of any of the 7 major cytochrome P450s (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4) based on full kinetic CYP inactivation assays IDE892 monotherapy Phase 1 escalation has cleared multiple dose cohorts with maximally efficacious target exposures anticipated at a favorable pill size and the MTD has not yet been reached. IDE892 monotherapy expansion is anticipated in Q3 2026 MTAP-deletion is estimated to occur in up to 40% of pancreatic cancer and ~15% of non-small cell lung cancer (NSCLC) SOUTH SAN FRANCISCO, Calif.
Similar companies
-
Gold Royalty Corp.
GROY
·
New York Stock Exchange Arca
Compare
-
Avino Silver & Gold Mines Ltd.
ASM
·
New York Stock Exchange Arca
Compare
-
Galiano Gold Inc.
GAU
·
New York Stock Exchange Arca
Compare
-
Lightwave Logic, Inc.
LWLG
·
NASDAQ
Compare
-
Vox Royalty Corp.
VOXR
·
NASDAQ
Compare
-
Lithium Argentina AG
LAR
·
New York Stock Exchange
Compare